News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
305,532 Results
Type
Article (28033)
Company Profile (104)
Press Release (277395)
Multimedia
Podcasts (32)
Webinars (3)
Section
Business (79901)
Career Advice (515)
Deals (11701)
Drug Delivery (53)
Drug Development (45943)
Employer Resources (46)
FDA (6706)
Job Trends (7288)
News (145346)
Policy (15043)
Tag
Academia (1885)
Academic (1)
Accelerated approval (4)
Adcomms (13)
Allergies (18)
Alliances (24018)
ALS (33)
Alzheimer's disease (582)
Antibody-drug conjugate (ADC) (147)
Approvals (6739)
Artificial intelligence (137)
Autoimmune disease (13)
Automation (3)
Bankruptcy (110)
Best Places to Work (6432)
BIOSECURE Act (15)
Biosimilars (62)
Biotechnology (88)
Bladder cancer (85)
Brain cancer (28)
Breast cancer (315)
Cancer (2448)
Cardiovascular disease (50)
Career advice (444)
Career pathing (6)
CAR-T (143)
Cell therapy (315)
Cervical cancer (22)
Clinical research (36784)
Collaboration (486)
Company closure (2)
Compensation (179)
Complete response letters (9)
COVID-19 (1376)
CRISPR (21)
C-suite (120)
Cystic fibrosis (41)
Data (1342)
Decentralized trials (2)
Denatured (9)
Depression (6)
Diabetes (90)
Diagnostics (3793)
Digital health (9)
Diversity (4)
Diversity, equity & inclusion (15)
Drug discovery (57)
Drug pricing (60)
Drug shortages (7)
Duchenne muscular dystrophy (27)
Earnings (25611)
Editorial (18)
Employer branding (6)
Employer resources (40)
Events (47897)
Executive appointments (320)
FDA (7385)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (389)
Gene editing (35)
Generative AI (10)
Gene therapy (105)
GLP-1 (232)
Government (3079)
Grass and pollen (1)
Guidances (57)
Healthcare (10721)
Huntington's disease (2)
IgA nephropathy (5)
Immunology and inflammation (60)
Indications (17)
Infectious disease (1444)
Inflammatory bowel disease (57)
Inflation Reduction Act (4)
Influenza (23)
Intellectual property (46)
Interviews (78)
IPO (5936)
IRA (22)
Job creations (1129)
Job search strategy (397)
Kidney cancer (11)
Labor market (12)
Layoffs (190)
Leadership (3)
Legal (2666)
Liver cancer (81)
Lung cancer (349)
Lymphoma (151)
Machine learning (5)
Management (15)
Manufacturing (135)
MASH (33)
Medical device (3379)
Medtech (3379)
Mergers & acquisitions (5963)
Metabolic disorders (210)
Multiple sclerosis (25)
NASH (1)
Neurodegenerative disease (21)
Neuropsychiatric disorders (4)
Neuroscience (735)
NextGen: Class of 2025 (3578)
Non-profit (3582)
Now hiring (8)
Obesity (87)
Opinion (98)
Ovarian cancer (84)
Pain (39)
Pancreatic cancer (90)
Parkinson's disease (41)
Partnered (12)
Patents (105)
Patient recruitment (69)
Peanut (6)
People (25553)
Pharmaceutical (20)
Pharmacy benefit managers (10)
Phase I (13116)
Phase II (15917)
Phase III (11455)
Pipeline (703)
Policy (87)
Postmarket research (1313)
Preclinical (5566)
Press Release (25)
Prostate cancer (115)
Psychedelics (6)
Radiopharmaceuticals (240)
Rare diseases (162)
Real estate (2038)
Recruiting (18)
Regulatory (10522)
Reports (15)
Research institute (1768)
Resumes & cover letters (61)
RNA editing (2)
RSV (21)
Schizophrenia (27)
Series A (54)
Series B (28)
Sickle cell disease (27)
Special edition (5)
Spinal muscular atrophy (45)
Sponsored (12)
Startups (1518)
State (2)
Stomach cancer (16)
Supply chain (23)
Tariffs (27)
The Weekly (23)
Vaccines (353)
Venture capitalists (17)
Weight loss (48)
Women's health (22)
Worklife (2)
Date
Today (87)
Last 7 days (422)
Last 30 days (1454)
Last 365 days (15482)
2025 (5472)
2024 (16828)
2023 (19050)
2022 (25228)
2021 (26823)
2020 (25864)
2019 (23475)
2018 (17429)
2017 (14184)
2016 (14046)
2015 (16287)
2014 (12291)
2013 (9825)
2012 (10264)
2011 (10859)
2010 (9653)
Location
Africa (331)
Alabama (21)
Alaska (3)
Arizona (83)
Arkansas (7)
Asia (19928)
Australia (3479)
California (2876)
Canada (930)
China (416)
Colorado (120)
Connecticut (144)
Delaware (107)
Europe (38934)
Florida (407)
Georgia (90)
Idaho (25)
Illinois (273)
India (17)
Indiana (153)
Iowa (6)
Japan (87)
Kansas (41)
Kentucky (17)
Louisiana (4)
Maine (5)
Maryland (519)
Massachusetts (1991)
Michigan (45)
Minnesota (124)
Mississippi (2)
Missouri (61)
Montana (12)
Nebraska (10)
Nevada (36)
New Hampshire (38)
New Jersey (973)
New Mexico (16)
New York (986)
North Carolina (331)
North Dakota (2)
Northern California (1340)
Ohio (81)
Oklahoma (2)
Oregon (12)
Pennsylvania (556)
Puerto Rico (5)
Rhode Island (11)
South America (389)
South Carolina (9)
South Dakota (1)
Southern California (1098)
Tennessee (32)
Texas (588)
United States (10954)
Utah (61)
Virginia (65)
Washington D.C. (26)
Washington State (317)
West Virginia (2)
Wisconsin (40)
305,532 Results for "national colorectal cancer roundtable nccrt".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
BMS Scores Two on Tuesday With Colorectal Cancer Approval, Court Win
The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action complaint over the blood cancer drug Pomalyst.
April 9, 2025
·
2 min read
·
Tristan Manalac
Cancer
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that could position them as new standards of care in certain subtypes of metastatic colorectal cancer.
January 27, 2025
·
2 min read
·
Tristan Manalac
Approvals
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival, calling it the “major efficacy outcome” of the trial.
January 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
April 28, 2025
·
5 min read
Press Releases
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
March 31, 2025
·
8 min read
Biotech Bay
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
23andMe Holding Co., a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance, the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community.
June 4, 2024
·
5 min read
Press Releases
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
March 19, 2025
·
5 min read
News
American Cancer Society Launches the National Prostate Cancer Roundtable to Address an Alarming Rise in Diagnoses
September 5, 2024
·
3 min read
BioMidwest
Namida Joins The American Cancer Society National Breast Cancer Roundtable
Namida Lab, Inc. has been accepted to the American Cancer Society National Breast Cancer Roundtable.
August 29, 2023
·
2 min read
Press Releases
Data from First-in-Human Trial targeting CISH, a Novel Immune Checkpoint, in Patients with Metastatic Colorectal Cancer Presented at 2025 American Association for Cancer Research (AACR) Annual Meeting
May 2, 2025
·
5 min read
1 of 30,554
Next
